<DOC>
	<DOCNO>NCT01015443</DOCNO>
	<brief_summary>The purpose study determine whether cancer vaccine tecemotide ( L-BLP25 ) addition best supportive care effective prolonging life Asian subject unresectable stage III non-small cell lung cancer comparison placebo plus best supportive care ( so-called placebo control study ) .</brief_summary>
	<brief_title>Cancer Vaccine Study Stage III , Unresectable , Non-small Cell Lung Cancer ( NSCLC ) Asian Population</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically cytologically document unresectable stage III nonsmall cell lung cancer ( NSCLC ) Documented stable disease objective response , accord Response Evaluation Criteria In Solid Tumors Version 1.0 ( RECIST v1.0 ) primary concomitant chemoradiotherapy unresectable stage III disease , within four week ( 28 day ) prior randomization Receipt concomitant chemoradiotherapy . The chemotherapypart must platinumbased , must administer minimum two cycle overlap radiotherapy ( one cycle last either 3 4 week depend chemotherapy regimen ) , minimum two platinumbased chemotherapy administration must give radiotherapy . Purely radio sensitizing dos chemotherapy acceptable . Radiotherapy must deliver radiation dose &gt; = ( great equal ) 50 Gray ( Gy ) . Induction consolidation chemotherapy allow give , account part primary thoracic chemoradiotherapy . Subjects must complete primary thoracic chemoradiotherapy least four week ( 28 day ) later 12 week ( 84 day ) prior randomization . Subjects receive prophylactic brain irradiation part primary chemoradiotherapy eligible Geographically accessible ongoing followup , commit comply designate visit An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 A platelet count &gt; = low limit normal site &gt; = 100 x 10^9 per liter ( /Liter ) ( whichever great ) ; white blood cell ( WBC ) &gt; = 2.5 x 10^9/Liter haemoglobin &gt; = 90 gram per liter ( g/L ) &gt; =18 year age ( minimum age legal consent consistent local regulation , minimum great [ &gt; ] 18 year age ) Other protocol define inclusion criterion could apply PreTherapies* : Prior sequential chemoradiotherapy Lungcancerspecific therapy ( include surgery ) primary chemoradiotherapy Immunotherapy ( e.g. , interferon , tumor necrosis factor [ TNF ] , interleukins , biological response modifier [ granulocyte macrophage colony stimulate factor { GMCSF } , granulocyte colony stimulate factor { GCSF } , macrophagecolony stimulate factor { MCSF } ] , monoclonal antibody ) within four week ( 28 day ) prior randomization Investigational systemic drug ( include offlabel use approve product ) within four week ( 28 day ) prior randomization Disease Status : Metastatic disease Malignant pleural effusion initial diagnosis and/or trial entry Past current history neoplasm lung carcinoma , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least 5 year Autoimmune disease A recognized immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; subject hereditary congenital immunodeficiency Any preexist medical condition require chronic steroid immunosuppressive therapy ( steroids treatment radiation pneumonitis allow ) Known active Hepatitis B infection and/or Hepatitis C infection Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) Physiological Functions : Clinically significant hepatic dysfunction Clinically significant renal dysfunction Clinically significant cardiac disease Splenectomy Infectious process opinion investigator could compromise subject 's ability mount immune response Standard Safety : Pregnant breastfeed woman , woman childbearing potential , unless use effective contraception determine investigator Known drug abuse alcohol abuse Participation another clinical trial ( exclude purely observational study ) within past 28 day Requires concurrent treatment nonpermitted drug Known hypersensitivity trial treatment ingredient Legal incapacity limit legal capacity Any reason , opinion investigator precludes subject participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Non-Small Cell Lung Carcinoma</keyword>
	<keyword>Tecemotide</keyword>
	<keyword>L-BLP25</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>placebo control</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>